A Phase 4 interventional study of Rescue Intravitreal Aflibercept Injection and Rescue Therapy with PDT, Laser or Intravitreal Steroids in Neovascular Polypoidal Choroidal Vasculopathy, sponsored by Southeast Retina Center, Georgia. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-15.
Sponsored by Southeast Retina Center, Georgia · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Polypoidal Choroidal Vasculopathy · United States.
Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2014, is one of 2 in phase 4, and was the 10th registered.
55 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 7 are open to participants now.
Browse Polypoidal Choroidal Vasculopathy studies →1 of the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States is open now. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 7–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Polypoidal Choroidal Vasculopathy studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 4 2
First in 2006; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 50 across 40 interventional studies indexed under Polypoidal Choroidal Vasculopathy.
Median enrollment 20 across the 12 interventional studies, 150 across the 1 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 9 most frequent:
Southeast Retina Center, Georgia is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Southeast Retina Center, Georgia has 3 studies filed under Polypoidal Choroidal Vasculopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.
This is an open-label, non-randomized, unmasked, study of IAI in patients with choroidal neovascularization secondary to polypoidal choroidal vasculopathy (PCV). Twenty treatment naïve and previously treated PCV eyes will be enrolled (only one study eye per patient will be enrolled). A maximum of 10 previously treated eyes will be enrolled. Consented, enrolled patients will be followed monthly. All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months. Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met. Starting at Month 3, patients can receive non-anti vascular endothelial growth factor (VEGF) rescue therapy (ie: Photodynamic Therapy (PDT), laser, intravitreal steroids) if the pre-defined criteria are met.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months.
Drug: Rescue Intravitreal Aflibercept Injection · Procedure: Rescue Therapy with PDT, Laser or Intravitreal Steroids
Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
Incidence and Severity
The primary objective of the study is the incidence and severity of ocular and systemic adverse events at Month 6.
Time frame: Month 6
Incidence and Severity
The primary objective of the study is the incidence and severity of ocular and systemic adverse events at Month 12.
Time frame: Month 12
Change in Best Corrected Visual Acuity (BCVA)
•The mean change in BCVA from Baseline to Month 6 and from Baseline up to 12 months
Time frame: Months 6 and 12
Change in Best Corrected Visual Acuity (BCVA)
•Proportion of patients gaining 5, 10 and 15 letters at Months 6 and 12
Time frame: Months 6 and 12
Change in Best Corrected Visual Acuity (BCVA)
•Proportion of patients losing 5,10, and 15 letters at Months 6 and 12
Time frame: Months 6 and 12
Photography Assessments
•Mean change from baseline in central subfield thickness at Months 6 and 12 as assessed on spectral domain optical coherence tomography (SD-OCT)
Time frame: Months 6 and 12
Photography Assessments
•Mean change from baseline in macular volume at Months 6 and 12 as assessed on SD-OCT
Time frame: Months 6 and 12
Photography Assessments
•Mean change from baseline in choroidal thickness at Months 6 and 12 through SD-OCT
Time frame: Months 6 and 12
Photography Assessments
•Proportion of patients with no evidence of pigment epithelial detachment (PED), intraretinal and subretinal fluid from choroidal neovascularization (CNV) as assessed by optical coherence tomography (OCT) at 6 and 12 months
Time frame: Months 6 and 12
Photography Assessments
•Mean change from baseline in the total area of CNV fluorescein angiographic leakage at months 6 and 12
Time frame: Months 6 and 12
Photography Assessments
•Fluorescein angiograms, indocyanine green (ICG) angiograms, OCT and fundus photographs at Months 6 and 12 compared to baseline as unchanged, resolved, improved, worsened, or cannot determine. See section 9.1.2.2
Time frame: Months 6 and 12
Photography Assessments
•Rate of polyp regression and resolution at 6 and 12 Months
Time frame: Months 6 and 12
Rescue Therapy
•Mean number of injections of IAI
Time frame: Month 12
Rescue Therapy
•Incidence of need and administration of rescue therapy with PDT, laser, or intravitreal steroids
Time frame: Month 12
Rescue Therapy
•Incidence and need of administration of additional IAI therapy
Time frame: Month 12
The record gives a start of Mar 2014, a primary completion of Mar 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polypoidal Choroidal Vasculopathy →
Southeast Retina Center, Georgia